[News Article]PharmAbcine was introduced today in The South China Morning Post-2018 South Korea Business Report.
Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at BOSTON CEO on May 10th, 2018.
PharmAbcine enters collaboration with MSD focused on clinical evaluation of TTAC-0001 in combination with KEYTRUDA® (pembrolizumab) in recurrent glioblastoma and breast cancer.
PharmAbcine was introduced today in The South China Morning Post-2018 South Korea Business Report.
Please see the attached file for more information.